Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Hønefoss – page 6

606 clinical trials in Hønefoss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Hønefoss at a glance
606
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

606 trials in Hønefoss

Open in trial search

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:BMN 333
  • Sponsor:Biomarin Pharmaceutical Inc.

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Stomatitis+1

Recruiting

A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bupivacaine hydrochloride monohydrate
  • Sponsor:OncoZenge AB

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Hønefoss

What the registry says about research in the country

01 Musculoskeletal Diseases

In Hønefoss, researchers are evaluating non‑pharmacologic and medication approaches for acute neck pain. The study compares chiropractic spinal manipulative therapy with standard use of NSAIDs to determine which method best reduces pain intensity during the treatment period.

  • Comparative effectiveness of manual therapy versus medication
  • Measurement of pain intensity and functional recovery
  • Patient‑reported outcome measures
  • Safety and feasibility of combined treatment strategies

Findings aim to guide clinicians in selecting optimal first‑line interventions for neck pain, potentially improving recovery speed and patient satisfaction.

02 Bacterial Infections and Mycoses

Clinical investigators are studying patients with suspected community‑acquired sepsis to assess whether a regimen of narrow spectrum β‑lactam antibiotics together with an aminoglycoside is safe and non‑inferior to standard broad spectrum antibiotics. The goal is to refine early treatment choices while minimizing unnecessary broad‑spectrum exposure.

  • Early antibiotic stewardship in severe infections
  • Safety profiling of combination therapy
  • Efficacy comparison with broad‑spectrum regimens
  • Impact on patient outcomes and hospital stay

Results could support more targeted antibiotic use, preserving effectiveness of broad‑spectrum agents and reducing resistance development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.